Rebif

Multiplying options for MS

Recommended pharmacological treatments included one of three interferons (Biogen Idec's Avonex or EMD Serono/Pfizer's Rebif, which are both formulations of interferon ß-1a, or Bayer's Betaseron, an

Grab attention

In the US, where the rules on DTC marketing are more relaxed, progressive brands such as EMD Serono's Rebif are tailoring their communications to what research shows their patients like. ... However, they began to note that patients preferred online

UK launch of RebiDose for treatment of MS

Merck Serono has launched the UK's first pre-filled, single-use disposable pen for the self-administration of Rebif. ... Merck's division for innovative prescription pharmaceuticals, Merck Serono, has launched the UK's first pre-filled, single-use

Drug delays conversion to MS

Results from a phase III study into Merck Serono's Rebif has shown it significantly delays conversion to multiple sclerosis. ... Rebif is not currently licensed for treating patients with a first clinical event suggestive of MS. .

Biogen Idec sues for patent infringement

Biogen Idec claims that the drugs Rebif (promoted by Pfizer and Serono), Betaseron (Bayer), and a version of Betaseron sold as Extavia by Novartis, infringe a patent issued in September 2009, ... Rebif generated global sales of $2.1bn in 2009, and

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]